NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, News, & Analysis

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) released its quarterly earnings data on Wednesday, February, 6th. The biotechnology company reported $1.25 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $1.46 by $0.21. The biotechnology company earned $69.89 million during the quarter, compared to analysts' expectations of $71.27 million. Enanta Pharmaceuticals had a return on equity of 22.78% and a net margin of 36.19%. The company's revenue for the quarter was up 83.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.59 EPS. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Enanta Pharmaceuticals.

6 equities research analysts have issued 12 month target prices for Enanta Pharmaceuticals' stock. Their predictions range from $80.00 to $133.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $102.60 in the next year. This suggests a possible upside of 7.1% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

News headlines about ENTA stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a news impact score of 1.7 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days.

Some companies that are related to Enanta Pharmaceuticals include Loxo Oncology (LOXO), Dr.Reddy's Laboratories (RDY), Marina Biotech (MRNA), Perrigo (PRGO), Catalent (CTLT), Amarin (AMRN), Nektar Therapeutics (NKTR), Alkermes (ALKS), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), GALAPAGOS NV/S (GLPG), Horizon Pharma (HZNP) and FibroGen (FGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), NVIDIA (NVDA), Zoetis (ZTS), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Gilead Sciences (GILD), Dollar Tree (DLTR), GW Pharmaceuticals PLC- (GWPH), Celgene (CELG) and Mastercard (MA).

Enanta Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.24%), First Manhattan Co. (3.50%), Dimensional Fund Advisors LP (3.21%), Krensavage Asset Management LLC (2.76%), Krensavage Asset Management LLC (2.75%) and Acadian Asset Management LLC (1.79%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Acadian Asset Management LLC, FMR LLC, Great Point Partners LLC, Mackenzie Financial Corp, First Trust Advisors LP, First Manhattan Co. and Barclays PLC. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Citigroup Inc., Candriam Luxembourg S.C.A., Two Sigma Investments LP, Krensavage Asset Management LLC, Krensavage Asset Management LLC, Millennium Management LLC and KBC Group NV. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $95.82.

Enanta Pharmaceuticals has a market capitalization of $1.86 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.

The official website for Enanta Pharmaceuticals is http://www.enanta.com.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]